TB-500: A Fragment Wearing a Larger Protein's Reputation

The short version

TB-500 is the name the peptide-research market uses for a seven-amino-acid fragment (Ac-LKKTETQ) taken from a much larger protein called Thymosin Beta-4, which the body releases from platelets and immune cells at the site of an injury. That larger, natural protein does have real human safety data behind it: a 40-person clinical trial found intravenous thymosin beta-4 well tolerated at doses up to 1,260 mg, with no serious adverse events ^[16]. The problem is that almost none of the studies showing tissue-repair benefits used the small fragment sold commercially as "TB-500" — they used the full-length protein, a much larger, differently behaving molecule.

That identity gap is the organizing fact of this page. What's reasonably well established: the parent protein binds and buffers a cellular building block called actin, and is tied in animal studies to faster wound closure, new blood-vessel growth, and less scarring ^[14][15][17]. What is not established: that the short fragment sold commercially as TB-500 reproduces those effects in a living human body. TB-500 is also prohibited in competitive sport.

What it is

TB-500, as sold, is a synthetic, N-terminally acetylated heptapeptide with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, corresponding to residues 17 through 23 of the endogenous 43-amino-acid protein Thymosin Beta-4 (gene TMSB4X). That LKKTETQ stretch is the conserved actin-binding motif shared across the beta-thymosin family of proteins. The identity distinction matters here more than almost anywhere else on this site: "TB-500" in commerce and in the analytical anti-doping literature specifically denotes this small heptapeptide (roughly 889 Daltons), while the overwhelming majority of published efficacy research was conducted using the full-length, roughly 4,963-Dalton protein. Wherever a finding on this page used the full-length protein rather than the marketed fragment, that is stated explicitly rather than blurred.

How it works

The full-length protein, Thymosin Beta-4, is the major peptide inside cells that sequesters monomeric (unassembled) actin — it binds a single actin molecule one-to-one, capping both ends to hold a buffered pool of unpolymerized actin in reserve and regulate the cytoskeleton, cell migration, and cell motility. In injury models, the protein and its LKKTETQ actin-binding region are associated with faster cell migration toward the wound, new blood-vessel growth (angiogenesis), anti-inflammatory and anti-apoptotic (cell-survival) signaling, reduced scar-forming myofibroblast activity, and recruitment of progenitor cells that help rebuild tissue. Its documented targets include monomeric actin itself, hair-follicle stem cells, vascular endothelial cells, heart-muscle and epicardial progenitor cells, and skin and corneal epithelium.

What is genuinely unresolved — and this site treats it as unresolved rather than assumed — is whether the isolated seven-amino-acid fragment marketed as TB-500 reproduces the full protein's effects at the concentrations used in research settings. No controlled human trial has tested that question directly.

What the research shows

The state-of-the-field review. A 2026 Sports Medicine narrative review of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance — which lists TB-500/Thymosin Beta-4 alongside BPC-157 among the unapproved compounds — concludes that many of these peptides show favorable tissue-repair outcomes in animal models, but that rigorous human safety data remain scarce, that there is real potential for harm, and that these compounds operate largely outside regulatory oversight ^[13].

Stroke recovery, full-length protein, rats. In male Wistar rats given an experimental stroke, intraperitoneal thymosin beta-4 (2, 12, or 18 mg/kg, starting 24 hours after the stroke and continuing every 3 days for four more doses) improved neurological function at the 2 and 12 mg/kg doses — a difference that held from day 14 through day 56 (p<0.05) — but the 18 mg/kg dose gave no significant benefit, and researchers modeled an optimal dose around 3.75 mg/kg. Higher was not better in this study ^[14].

Mechanism review. A 2012 review consolidates the case for the full-length protein: it binds actin and promotes cell mobilization and migration and stem-cell activity, decreases myofibroblast numbers (meaning less scar formation), is released by platelets and macrophages after injury to limit cell death, inflammation, and microbial growth, and promotes angiogenesis — the rationale behind clinical trials in dermal wounds, corneal injury, and heart and central-nervous-system repair ^[15].

Human safety data (full-length protein). In a randomized, placebo-controlled Phase 1 study, synthetic thymosin beta-4 given intravenously to 40 healthy volunteers — a single dose, then daily for 14 days at 42, 140, 420, or 1,260 mg across four cohorts of 10 — was well tolerated, with only infrequent mild-to-moderate adverse events and no dose-limiting toxicities or serious adverse events. Pharmacokinetics were dose-proportional, with half-life increasing at higher doses ^[16]. This is the strongest human evidence connected to TB-500's family of compounds, and it was conducted with the full-length protein, not the marketed fragment.

Structural basis. High-resolution crystallography (2 Å) of a related protein complex bound to actin established that thymosin beta-4 forms a one-to-one complex with monomeric actin and sequesters it by capping both ends, preventing polymerization — confirming the structural mechanism behind the protein's actin-buffering role, driven by a shared actin-interacting motif ^[17].

Reported effects, cautions & safety

The reports below describe what people in research-peptide and athletic communities say they experience with TB-500 — this is anecdotal, not clinical evidence, drawn from peptide-user forums, athletic and biohacker community blogs, and research-supplier review pages rather than controlled studies, and none of it involves a dose recommendation.

Reported benefits (anecdotal): Faster recovery from tendon, ligament, and muscle injuries is the most common reason people in these communities say they use TB-500 — nagging soft-tissue injuries reportedly feeling better and returning to activity sooner than expected, though reported timelines vary widely person to person. Less joint pain and stiffness, and easier range of motion, are frequently described, especially among people with general wear-and-tear stiffness. Some report improved overall flexibility and mobility during training, and a smaller group describes a general sense of reduced inflammation or "calmed down" post-workout soreness. Others mention faster-seeming healing of cuts, surgical sites, or skin irritation, which lines up loosely with what animal wound studies show for the parent protein, and a smaller group reports hair regrowth over four to eight weeks, often alongside other interventions.

Reported adverse effects (anecdotal): By far the most common complaint is a small, sore, or slightly swollen spot at the injection site, usually gone within a day or two — typical of injected peptides generally, not unique to TB-500. Many users report temporary tiredness or lethargy for a day or two, especially early in a so-called loading phase, that fades as the body adjusts. Some describe a brief head rush, lightheadedness, or mild headache shortly after injecting. A handful report a brief flu-like feeling in the first day or two. Nausea is mentioned by a minority, more often at larger amounts. A small number describe an old injury feeling more "active" or noticeable for a week or two, and a small number mention short-lived mood changes during early use.

Cited cautions: Human safety of the marketed TB-500 fragment specifically is essentially unstudied — no completed controlled human trial exists for the fragment itself, and the 2026 review of unapproved musculoskeletal peptides concludes that compounds in this category carry potential for serious harm and operate largely outside regulatory oversight, even where animal-model results look promising ^[13][16]. There is a theoretical cancer and tumor-growth concern: the parent protein, thymosin beta-4, is overexpressed in several cancers and has been linked in research to tumor spread and to new blood-vessel growth that feeds tumors, so the same pro-migration, pro-angiogenesis actions that may aid repair could, in principle, also support tumor progression — a mechanism-based concern that has not been measured for TB-500 specifically in people. TB-500 is prohibited in competitive sport under World Anti-Doping Agency peptide and growth-factor categories, and anti-doping laboratories have developed methods to detect it and its breakdown products ^[13]. Reported community benefits may also overstate what the peptide actually does: at least one honest animal study found more tissue regeneration did not translate into better function. And a caution specific to this compound above all others on this desk: TB-500 is a short fragment, not the full Thymosin Beta-4 protein, and it is a real extrapolation — not yet confirmed — to assume the fragment reproduces effects measured almost entirely in the larger molecule ^[15]. Research-grade material sold as TB-500 is also not made to medicine-grade standards, and identity, purity, and exact sequence can vary meaningfully between suppliers, adding an extra layer of uncertainty on top of the biology itself.

Where it fits in Recovery & Tissue Repair

TB-500 is the hype-versus-data case study on this desk. Its underlying biology — actin buffering, cell migration, angiogenesis — is genuinely interesting and reasonably well studied, but almost entirely in a larger relative protein, not in the small fragment actually sold under this name. That puts it in sharp contrast with GHK-Cu, whose human trials at least test the exact form being sold, and with KPV, whose evidence is entirely preclinical but at least studies the exact molecule marketed. Read the full comparison to see how the three stack up on evidence, legal status, and the single caution that matters most for each.